Pfizer Cutting Cost Of R&D Under Efficiency Program; Output To Double
Executive Summary
Pfizer hopes to double output from its research and development operations while holding R&D costs in line with historic increases, CEO Hank McKinnell told investors July 20
You may also be interested in...
Pfizer Sets Sights On Becoming Top Five Biologics Player By 2010
Pfizer is emphasizing a diversified approach, focusing on both small molecules and biotech products, as it attempts to regain investor confidence in the company's growth potential
Pfizer Sets Sights On Becoming Top Five Biologics Player By 2010
Pfizer is emphasizing a diversified approach, focusing on both small molecules and biotech products, as it attempts to regain investor confidence in the company's growth potential